Reducing Late-Stage Biologic Failure with Immune Assays- An Interview with Harald Kropshofer
There have been some high profile cases of antibodies causing severe reactions, as well as posing a high risk to patients, these late stage failures are hugely costly. Is there a way to prevent or predict these immune reactions to biologics? We spoke to Harald Kropshofer Senior Personalized Healthcare Leader, Pharmaceutical Development F. Hoffman La Roche about his work on whole blood assays to assess cytokine response and t cell dependant responses and how these can be integrated into the drug...
To continue reading this story get free access